Copyright © 2006, European Society of Cardiology
Phenotypic adaptation of the late preconditioned heart: Myocardial oxygen consumption is reduced
aINSERM U660, Créteil, F-94010, France
bEcole Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
cLaboratoire de Pharmacologie, Faculté de Médecine de Créteil, Université Paris XII, Créteil, F-94000, France
dFédération de Cardiologie, Hôpital Henri Mondor, Créteil, France
* Corresponding author. Laboratoire de Pharmacologie, INSERM U660, Faculté de Médecine de Créteil, 8, rue du Général Sarrail, 94010 Creteil Cedex, France. Tel.: +33 1 49 81 36 51; fax: +33 1 49 98 17 77. Email address: berdeaux{at}im3.inserm.fr
Objectives Although the signalling pathways of late preconditioning have been extensively investigated, its consequence for myocardial metabolism remains unknown. Thus, myocardial oxygen consumption (MVO2) was evaluated before and under late preconditioning.
Methods In 7 chronically instrumented dogs, we measured MVO2 in vivo at baseline and during inotropic stimulation with dobutamine (10 and 20 µg/kg/min, i.v.) before (Day 0) and 24 h after (Day 1) a 10-min circumflex coronary artery occlusion.
Results At Day 0, dobutamine dose-dependently increased the triple product (heart rate x left ventricular systolic pressure x left ventricular maximum dP/dt), MVO2, coronary blood flow, and coronary sinus pO2. At Day 1, the triple product was similar at baseline and at each dose of dobutamine but MVO2 was significantly blunted as compared to Day 0 (– 15±4%, – 22±3% and – 19±4% at baseline, dobutamine 10 and 20 µg/kg/min, respectively). Importantly, the relationship between MVO2 and triple product was significantly rightward shifted with late preconditioning, i.e., MVO2 was reduced for any level of triple product. At Day 1, the relationship between coronary blood flow and MVO2 was not altered as compared to Day 0 but coronary sinus pO2 was significantly increased vs. Day 0 for any level of coronary blood flow, suggesting that late preconditioning exerted no vasomotor effect but rather changed myocardial oxygen handling. These effects were abolished by administration of S-methyl-isothiourea (1.5 mg/kg, i.v.), a iNOS inhibitor.
Conclusion This study demonstrates that ischemic late preconditioning is characterized by a major reduction in MVO2, both at baseline and under inotropic stimulation. NO from iNOS contributes to this modification of metabolic phenotype.
KEYWORDS Oxygen consumption; Stunning; Nitric oxide; Preconditioning
Time for primary review 20 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G. G. Abdukeyum, A. J. Owen, and P. L. McLennan Dietary (n-3) Long-Chain Polyunsaturated Fatty Acids Inhibit Ischemia and Reperfusion Arrhythmias and Infarction in Rat Heart Not Enhanced by Ischemic Preconditioning J. Nutr., October 1, 2008; 138(10): 1902 - 1909. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Galkin and S. Moncada S-Nitrosation of Mitochondrial Complex I Depends on Its Structural Conformation J. Biol. Chem., December 28, 2007; 282(52): 37448 - 37453. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Brown and V. Borutaite Nitric oxide and mitochondrial respiration in the heart Cardiovasc Res, July 15, 2007; 75(2): 283 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lucats, L. Vinet, A. Bize, X. Monnet, D. Morin, J. B. Su, P. Rouet-Benzineb, O. Cazorla, J.-J. Mercadier, L. Hittinger, et al. The inotropic adaptation during late preconditioning against myocardial stunning is associated with an increase in FKBP12.6 Cardiovasc Res, February 1, 2007; 73(3): 560 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Monnet, L. Lucats, P. Colin, G. Derumeaux, J.-L. Dubois-Rande, L. Hittinger, B. Ghaleh, and A. Berdeaux Reduction in postsystolic wall thickening during late preconditioning Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H158 - H164. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Garcia-Dorado, J. Vinten-Johansen, and H. M. Piper Bringing preconditioning and postconditioning into focus Cardiovasc Res, May 1, 2006; 70(2): 167 - 169. [Full Text] [PDF] |
||||



